Bart Borek

Bart is an Associate Director at Vertex Pharmaceuticals, where they lead quantitative pharmacology initiatives supporting rare disease research and development, from target selection through Phase IV Studies. With extensive expertise in integrative biology, pharmacometrics, and regulatory science they have contributed to the approval of transformative therapies including TRIKAFTA and CASGEVY, applying data-driven approaches to guide study design and development decisions.